Clincosm LogoSign in Get a demo

Genome-wide Association Study

Sponsor
Samsung Medical Center (Other)
Overall Status
Withdrawn
CT.gov ID
NCT01498757
Collaborator
(none)
0
Enrollment
1
Location
6
Duration (Months)
0
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

To explore biomarkers predictive of clinical response to Taxane/5-FU/platinum based chemotherapy in esophageal squamous cell carcinoma. To identify negative predictive markers to 5-FU/platinum/Taxane. To elucidate signal transduction pathway attributable to 5-FU/platinum/Taxane resistance. To analyze correlation between the quantity of circulating tumor cells and circulating endothelial cell precursors and treatment response to Taxane/5-FU/platinum based chemotherapy.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    0 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Genome-wide Association Study to Predict Treatment Response for Chemotherapy in Esophageal Squamous Cell Carcinoma
    Study Start Date :
    Jan 1, 2012
    Actual Primary Completion Date :
    Jun 1, 2012
    Actual Study Completion Date :
    Jul 3, 2012

    Arms and Interventions

    Arm Intervention/Treatment
    Patients treated with Taxane/5-FU/platinum based chemo.

    Outcome Measures

    Primary Outcome Measures

    1. Biomarkers predictive [24months]

      Biomarkers predictive of clinical response to Taxane or 5-fluorouracil or platinum based chemotherapy.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Histological confirmed esophageal squamous cell carcinoma

    • Patients treated with Taxane or 5-FU or platinum based chemotherapy.

    • provision of a signed written informed consent.

    Exclusion Criteria:

    • patients not signed written informed consent.

    • patient unacceptable for study in the judgement of the investigator.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Samsung medical Center Seoul Korea, Republic of

    Sponsors and Collaborators

    • Samsung Medical Center

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Jeeyun Lee, Professor of Medicine, Sungkyunkwan University School of Medicine, Department of Hematology and Oncology, Samsung Medical Center
    ClinicalTrials.gov Identifier:
    NCT01498757
    Other Study ID Numbers:
    • 2011-05-076
    First Posted:
    Dec 23, 2011
    Last Update Posted:
    May 21, 2019
    Last Verified:
    May 1, 2019
    Additional relevant MeSH terms:
    Carcinoma
    Carcinoma, Squamous Cell
    Esophageal Squamous Cell Carcinoma

    Study Results

    No Results Posted as of May 21, 2019